Shortening Treatment for Tuberculosis — Back to Basics

With approximately 8 million incident cases and 1.3 million deaths each year, increasing drug resistance, and exacerbating coexisting conditions such as the human immunodeficiency virus–acquired immunodeficiency syndrome and diabetes, tuberculosis continues to pose a massive threat to global health....

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 371; no. 17; pp. 1642 - 1643
Main Authors Warner, Digby F, Mizrahi, Valerie
Format Journal Article
LanguageEnglish
Published Boston Massachusetts Medical Society 23.10.2014
Subjects
Chemotherapy
Diabetes mellitus
Disease resistance
Drug dosages
Drug resistance
Ethambutol
HIV
Human immunodeficiency virus
Isoniazid
Medical treatment
Pyrazinamide
Rifampin
Tuberculosis
Online AccessGet full text

Cover

More Information
Summary:With approximately 8 million incident cases and 1.3 million deaths each year, increasing drug resistance, and exacerbating coexisting conditions such as the human immunodeficiency virus–acquired immunodeficiency syndrome and diabetes, tuberculosis continues to pose a massive threat to global health. In the absence of a vaccine to provide long-term protection, control of drug-susceptible tuberculosis is largely dependent on a standard 6-month chemotherapy regimen that has been in use for more than three decades. Any experimental therapy designed to modify this short-course regimen — which comprises a 2-month intensive phase with four drugs (rifampin, isoniazid, pyrazinamide, and ethambutol) followed by a 4-month . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMe1410977